Anavex Life Sciences Receives FDA Clearance to Proceed Ahead With Its Planned Clinical Trial Under Its Investigational New Drug Application For ANAVEX 2-73 For Fragile X Syndrome
Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with significant unmet
Anavex got permission from the FDA to test a new medicine for Fragile X Syndrome. This means the company can move forward with its plan, which is a normal step in drug development.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.